Form 8-K - Current report:
SEC Accession No. 0001493152-25-009571
Filing Date
2025-03-07
Accepted
2025-03-07 16:30:33
Documents
19
Period of Report
2025-03-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 60733
2 ex4-1.htm EX-4.1 111681
3 ex4-2.htm EX-4.2 123442
4 ex4-3.htm EX-4.3 16000
5 ex10-1.htm EX-10.1 270077
6 ex10-2.htm EX-10.2 57468
  Complete submission text file 0001493152-25-009571.txt   952401

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE zvsa-20250304.xsd EX-101.SCH 3012
8 XBRL LABEL FILE zvsa-20250304_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE zvsa-20250304_pre.xml EX-101.PRE 24163
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3822
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 25720578
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)